Jennison Associates
KYTX icon

Jennison Associates’s Kyverna Therapeutics KYTX Stock Holding History

Jennison Associates’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,398,659
Closed -$34.7M – 611
2024
Q1 		$34.7M Buy
+1,398,659
New +$39M 0.02% 273

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jennison Associates's KYTX Position: Q2 2024 in Review

Jennison Associates sold out of Kyverna Therapeutics (KYTX) in Q2 2024, closing a stake of 1,398,659 shares — an estimated $34.7M sold.

Jennison Associates first reported a position in KYTX in Q1 2024 and held it in 1 quarter. The position peaked at $34.7M in Q1 2024. 88 funds tracked by Wall St. Rank hold KYTX as of Q2 2024.

  • Jennison Associates reported no remaining Kyverna Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Jennison Associates sold 1,398,659 Kyverna Therapeutics shares in Q2 2024, an estimated $34.7M.
  • Jennison Associates first reported a position in Kyverna Therapeutics in Q1 2024 and held it in 1 quarter.
  • Jennison Associates's Kyverna Therapeutics position peaked at $34.7M in Q1 2024.
  • 88 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2024.

Based on Jennison Associates's 13F filing for Q2 2024, filed 5 Aug 2024.